Deep Venous Thrombosis Clinical Trial
Official title:
Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT
Verified date | January 2024 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to develop strategies that will improve outcomes for patients with deep vein thrombosis (DVT), using in vivo FDG-PET inflammation imaging to better predict the development of the post-thrombotic syndrome (PTS). New approaches are needed to improve the outcomes of patients with DVT, a disease that affects up to 600,000 patients per year in the US alone. DVT acutely places patients at risk of death from pulmonary embolism and causes 50,000 deaths annually in the US. Moreover, up to 30-50% of patients will develop PTS, an illness characterized by inflammation-driven fibrotic vein wall injury, and persistent thrombus obstruction. PTS occurs despite anticoagulant therapy, and produces chronic disability from leg pain, heaviness, edema, skin pigmentation, and ulcers; some patients may even require amputation. PTS impairs quality of life to the same extent as chronic obstructive pulmonary disease or diabetes. Therefore new diagnostic insights into PTS are urgently needed. There are several major challenges to improve outcomes in PTS: A) Limited in vivo knowledge regarding inflammation and the development of PTS; B) L Lack of predictive approaches to identify patients at high risk for PTS that will preferentially benefit from novel therapies. Recently, our laboratories have harnessed FDG-PET molecular imaging to illuminate DVT inflammation in vivo, and to provide a new strategy to diagnose recurrent DVT, a vexing clinical problem (Hara et al. Circulation 2014). We now propose to further develop FDG-PET to improve outcomes in DVT and PTS. The objective of this application is to develop FDG-PET as an inflammation imaging approach to assess DVT inflammation and predict risk of developing PTS in human subjects; Hypothesis 1A: Inflammatory activity in DVT (quantified acutely, using FDG-PET imaging within 0-7 days after DVT) will predict PTS incidence (primary) and severity (secondary) within a 24 month follow-up period. Hypothesis 1B: Inflammatory activity in DVTs (quantified sub-acutely, using FDG-PET imaging within 21-28 days after DVT), will predict PTS incidence and severity. Eighty patients with DVT will be imaged using FDG-PET/CT acutely (0-7 days of DVT diagnosis), and sub-acutely (21-28 days after diagnosis). Subjects will be evaluated repeatedly for up to 2 years to detect clinical evidence of PTS (Villalta score), ultrasound findings for structural venous injury, and soluble biomarkers of systemic inflammation. Subsequently, we will evaluate the relationship between FDG DVT activity and the development of PTS.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | March 30, 2025 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: - Age above 30 - Patient presents with a first symptomatic, proximal DVT (with or without concurrent distal DVT or pulmonary embolism). Exclusion Criteria: - Patient has May-Thurner syndrome - Patient has an expected life span of < 6 months - Patient can't receive anticoagulation therapy - Patient received thrombolytic therapy for the initial treatment of acute DVT - Patient has DVT signs of symptoms that occur more than 1 week prior to presentation, as assessed by clinical history - Renal dysfunction (Serum creatinine > 1.5 mg/ml or estimated creatinine clearance < 60 ml/min) |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Hara T, Truelove J, Tawakol A, Wojtkiewicz GR, Hucker WJ, MacNabb MH, Brownell AL, Jokivarsi K, Kessinger CW, Jaff MR, Henke PK, Weissleder R, Jaffer FA. 18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recu — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PTS incidence | Incidence of PTS (by Villalta score of =5) at any time during 24 months of observation after diagnosis of first proximal DVT | 24 month follow-up period | |
Secondary | PTS severity | Maximal severity of PTS (by Villalta score) during 24 month observation | 24 month follow-up period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT02889562 -
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
|
Phase 2/Phase 3 | |
Completed |
NCT00812370 -
The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids
|
Phase 1 | |
Completed |
NCT01333618 -
Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter
|
N/A | |
Completed |
NCT02552420 -
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism
|
Phase 2/Phase 3 | |
Completed |
NCT00178789 -
Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis
|
Phase 1/Phase 2 | |
Completed |
NCT03251963 -
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
|
Phase 2 | |
Completed |
NCT03286985 -
The Prevalence and Incidence of DVT in General ICU
|
||
Completed |
NCT04414332 -
Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
|
||
Completed |
NCT02211326 -
Genotype-guided Warfarin Individualized Treatment
|
N/A | |
Completed |
NCT03296280 -
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
|
||
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Completed |
NCT00628576 -
Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
|
Phase 3 | |
Completed |
NCT04979026 -
Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement
|
N/A | |
Active, not recruiting |
NCT02318472 -
Early Mobilization After Achilles Tendon Rupture
|
N/A | |
Completed |
NCT01221805 -
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
|
Phase 4 | |
Recruiting |
NCT03740633 -
Functional Training for the Prevention of Deep Venous Thrombosis
|
Phase 3 | |
Completed |
NCT03707665 -
Deep Venous Thrombosis Screening in the ICU by Nurses
|
||
Recruiting |
NCT05171049 -
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
|
Phase 3 | |
Completed |
NCT01542723 -
Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy
|
N/A |